title: Complete remission of psoriasis following bevacizumab therapy for colon cancer.
abstract: Bevacizumab is a monoclonal antibody against vascular endothelial growth factor (VEGF), which is used to treat several cancers. Currently, experience with anti-VEGF treatment for psoriasis is limited, and no published reports on this use exist. We describe a patient with metastatic colon cancer and psoriasis who experienced complete remission of psoriasis during treatment with bevacizumab and combination chemotherapy without any other treatment for psoriasis. These data suggest that bevacizumab may be a promising therapeutic agent for the treatment of psoriasis.
authors.affiliation: Department of Dermatology and Venerology, School of Medicine Antalya, Antalya, Turkey. aakman@akdeniz.edu.tr
authors.forename: A
authors.initials: A
authors.lastname: Akman
authors.forename: E
authors.initials: E
authors.lastname: Yilmaz
authors.forename: H
authors.initials: H
authors.lastname: Mutlu
authors.forename: M
authors.initials: M
authors.lastname: Ozdogan
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003110:Colonic Neoplasms / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D033162:Incidental Findings; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy*; D012074:Remission Induction; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab